ClinicalTrials.Veeva

Menu
A

Alivation Research, LLC | Lincoln, NE

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

SPN-812
Ecopipam
Lumateperone
Cariprazine
d-MPH
Psilocybin
SP-624
dexmethylphenidate
Viloxazine
Levomilnacipran

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

12 of 52 total trials

A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression (RECOVER)

Objectives of this study are to determine whether active VNS Therapy treatment is superior to a no stimulation control in producing a reduction in ba...

Enrolling
Treatment Resistant Depression
Device: Vagus Nerve Stimulation (VNS)

This is a Phase 2B clinical study evaluating the effectiveness and safety of SP-624 as compared to placebo in the treatment of adults with Major Depr...

Active, not recruiting
Major Depressive Disorder
Drug: SP-624
Drug: Placebo

The primary objective of this study is to evaluate the long-term safety and tolerability of ecopipam tablets in children (greater than or equal to \[...

Active, not recruiting
Tourette Syndrome
Drug: Ecopipam

This is a master protocol for 3 independent, seamlessly enrolling, multicenter, randomized, double-blind, placebo-controlled, parallel-group studies...

Enrolling
Alzheimer's Disease Psychosis
Drug: Placebo
Drug: ACP-204

Efficacy, Safety, and Tolerability of a single administration of COMP360 in participants with treatment-resistant depression (TRD)

Active, not recruiting
Treatment Resistant Depression
Drug: Psilocybin

Efficacy, Safety, and Tolerability of two administrations of COMP360 in participants with treatment-resistant depression (TRD)

Active, not recruiting
Treatment Resistant Depression
Drug: Psilocybin

The purpose of this study is to test the long-term safety of rimegepant in the acute treatment of migraine in children and adolescents (≥ 6 to \< 18...

Enrolling
Acute Treatment of Migraine
Drug: Rimegepant (PF-07899801)

This is a multicenter, randomized, double-blind, placebo-controlled study in pediatric patients who are experiencing major depressive episodes (MDEs)...

Enrolling
Bipolar Depression
Drug: Lumateperone
Drug: Placebo

This is a multicenter, randomized, double-blind, placebo-controlled study in pediatric patients aged 5 to 17 years with a primary diagnosis of irrita...

Enrolling
Irritability Associated With Autism Spectrum Disorder
Drug: Lumateperone low dose
Drug: Lumateperone high dose

The purpose of this study is to test the safety and efficacy of BHV-3000 versus placebo in the acute treatment of moderate or severe migraine in chil...

Enrolling
Pediatric Migraine
Drug: Rimegepant/BHV3000
Drug: Matching placebo

This is a multicenter, global, 26-week, open-label study to assess the safety and tolerability of lumateperone in pediatric patients with schizophren...

Enrolling
Autism Spectrum Disorder
Schizophrenia
Drug: Lumateperone

Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population in the United States. The purpose of this study is t...

Enrolling
Bipolar I or II Disorder
Drug: ABBV-932

Trial sponsors

AbbVie logo
Supernus Pharmaceuticals logo
E
Abbott logo
Intra-Cellular Therapies logo
LivaNova logo
Akili Interactive Labs logo
Allergan logo
C
C

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems